Mindfulness-Enhanced Dual-Task Training in PD-MCI

Launched by NANJING MINGZHOU REHABILITATION HOSPITAL · Apr 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new approach called Mindfulness-Enhanced Dual-Task Training to see if it can help improve thinking and movement skills in adults with Mild Cognitive Impairment (MCI) related to Parkinson's Disease (PD). The researchers are trying to find out if combining mindfulness techniques with dual-task training—where participants perform two tasks at once—can lead to better results than just doing dual-task training or regular motor task training alone.

To participate in the study, individuals need to be between 55 and 75 years old and have a confirmed diagnosis of Parkinson's Disease. They should also have mild cognitive impairment, as indicated by certain scores on a cognitive test. Participants will undergo treatment for four weeks and will be evaluated before and after the training to measure any changes in their cognitive and motor functions. This study is not yet recruiting participants, but it aims to help improve the lives of those with PD-related cognitive challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: Between 55 and 75 years.
• • Disease Diagnosis: Clinically diagnosed with Idiopathic Parkinson's Disease (PD) according to the UK Parkinson's Disease Society Brain Bank Criteria.
• • Disease Stage: Hoehn \& Yahr (H\&Y) stages 1 to 2.5.
• • Cognitive Function: Montreal Cognitive Assessment (MoCA) score between 23 and 26, indicating mild cognitive impairment (MCI).
• • Medication Stability: Stable doses of antiparkinsonian medications for at least 4 weeks prior to screening.
• • Subjective Cognitive Complaints: Self-reported or informant-reported cognitive decline persisting for at least 6 months.
• • Ambulatory Ability: Able to walk independently, with or without assistive devices.
• • Sensory Abilities: Adequate vision and hearing to comply with study procedures.
• • Informed Consent: Willingness to provide written informed consent and comply with study requirements.
• Exclusion Criteria:
• • Other Neurological Disorders: Presence of other neurological conditions that could affect cognitive function, such as Alzheimer's disease, stroke, or brain tumors.
• • Psychiatric Conditions: Severe psychiatric disorders, including major depressive disorder or schizophrenia.
• • Substance Abuse: Recent history of drug or alcohol abuse.
• • Serious Medical Conditions: Uncontrolled hypertension, diabetes, heart disease, or other conditions that could interfere with study participation or outcomes.
• • Severe Cognitive Impairment: Diagnosis of Parkinson's Disease Dementia (PDD).
• • Other Factors Affecting Cognition: Recent head trauma, uncontrolled thyroid dysfunction, vitamin B12 deficiency, or other conditions known to affect cognitive function.
• • Deep Brain Stimulation (DBS): History of DBS treatment. Participation in Other Clinical Trials: Participation in another clinical trial that could interfere with this study within the last 3 months.